NeurologyLive Covers New Clinical Utility Study of the Syn-One Test®
NeurologyLive covers recent findings showing the clinical utility of CND Life Sciences’ Syn-One Test–and how clinicians can use it to inform patient referrals to physical, occupational and speech therapy.
“Our study demonstrated that synuclein skin biopsy influenced the diagnosis or management in 78% of cases, underscoring the potential of the Syn-One test to change the paradigm in diagnosing these conditions, providing greater clarity, and ensuring patients receive appropriate care and treatment options,” said Jonathan R. Isaacson, MD, who led the study at the Center of Autonomic and Peripheral Nerve Disorders at Beth Israel Deaconess Medical Center (BIDMC).
Coauthor Roy Freeman, MD, professor of neurology, director of the Center for Autonomic and Peripheral Nerve Disorders at BIDMC shared how this can benefit patients. “This important evidence supports how this test can become a useful diagnostic tool in community settings to evaluate patients with signs and symptoms of these challenging diseases and triage them to more specialized care when needed.”
The article also links to an interview with neurologist Sameea Husain-Wilson, DO –who has been using the Syn-One test for several months at her institution– and has shared why its ability to quantify the presence or absence of α-synuclein is critical for movement disorder specialists worldwide.
Get the full story here.
Learn more about the Syn-One Test®
